ATE277635T1 - Reinigungsverfahren von verbindeten ig fraktionen mit immunomodulierender aktivität - Google Patents

Reinigungsverfahren von verbindeten ig fraktionen mit immunomodulierender aktivität

Info

Publication number
ATE277635T1
ATE277635T1 AT00401601T AT00401601T ATE277635T1 AT E277635 T1 ATE277635 T1 AT E277635T1 AT 00401601 T AT00401601 T AT 00401601T AT 00401601 T AT00401601 T AT 00401601T AT E277635 T1 ATE277635 T1 AT E277635T1
Authority
AT
Austria
Prior art keywords
fractions
purification process
invention concerns
reactivity
immunomodulating activity
Prior art date
Application number
AT00401601T
Other languages
English (en)
Inventor
Dominique Bourel
Martine Bruley-Rosset
Frederic Dhainaut
Jacky Lirochon
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9907153A external-priority patent/FR2794460A1/fr
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Application granted granted Critical
Publication of ATE277635T1 publication Critical patent/ATE277635T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/965—Chemistry: molecular biology and microbiology involving idiotype or anti-idiotype antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/822—Identified hapten
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00401601T 1999-06-07 2000-06-07 Reinigungsverfahren von verbindeten ig fraktionen mit immunomodulierender aktivität ATE277635T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907153A FR2794460A1 (fr) 1999-06-07 1999-06-07 Procede de preparation de nouvelles fractions d'igg humaines possedant une activite immunomodulatrice
FR9916632A FR2794461B1 (fr) 1999-06-07 1999-12-29 Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice

Publications (1)

Publication Number Publication Date
ATE277635T1 true ATE277635T1 (de) 2004-10-15

Family

ID=26234979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00401601T ATE277635T1 (de) 1999-06-07 2000-06-07 Reinigungsverfahren von verbindeten ig fraktionen mit immunomodulierender aktivität

Country Status (12)

Country Link
US (1) US6932969B1 (de)
EP (1) EP1059088B1 (de)
JP (1) JP2003519619A (de)
AT (1) ATE277635T1 (de)
AU (1) AU780138B2 (de)
CA (1) CA2376335A1 (de)
DE (1) DE60014239T2 (de)
DK (1) DK1059088T3 (de)
ES (1) ES2228425T3 (de)
FR (1) FR2794461B1 (de)
PT (1) PT1059088E (de)
WO (1) WO2000074717A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10127712A1 (de) * 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
FR2832155B1 (fr) * 2001-11-09 2004-07-09 Lab Francais Du Fractionnement Anticorps stimulant la production d'il-1ra
US20040101909A1 (en) * 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
FR2939667B1 (fr) 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
EP2258727A1 (de) 2009-05-27 2010-12-08 Wezen Biopharmaceuticals S.r.l. A Socio Unico Immunglobulinzubereitung zur Behandlung einer Autoimmunerkrankung und Immunsystemstörungen
US20100330102A1 (en) 2009-06-26 2010-12-30 Wezen Biopharmaceuticals Srl A Socio Unico Immunoglobulin preparation for the treatment of hiv-1 infection
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
EP3638296A1 (de) 2017-06-16 2020-04-22 The University Of Chicago Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
US11628204B2 (en) 2017-12-27 2023-04-18 The Johns Hopkins University Preventing cytokine release syndrome
EP3790577A4 (de) 2018-05-09 2022-04-27 The University of Chicago Zusammensetzungen und verfahren im zusammenhang mit immuntoleranz
CN116159340B (zh) * 2022-12-16 2026-06-12 浙江大学 一种用于体积排阻色谱法的缓冲液

Also Published As

Publication number Publication date
AU5538700A (en) 2000-12-28
WO2000074717A1 (fr) 2000-12-14
DK1059088T3 (da) 2005-02-07
ES2228425T3 (es) 2005-04-16
CA2376335A1 (fr) 2000-12-14
US6932969B1 (en) 2005-08-23
PT1059088E (pt) 2005-02-28
DE60014239T2 (de) 2005-08-25
DE60014239D1 (de) 2004-11-04
JP2003519619A (ja) 2003-06-24
EP1059088A1 (de) 2000-12-13
EP1059088B1 (de) 2004-09-29
FR2794461B1 (fr) 2004-01-23
AU780138B2 (en) 2005-03-03
FR2794461A1 (fr) 2000-12-08

Similar Documents

Publication Publication Date Title
DE60014239D1 (de) Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität
PT712863E (pt) Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica
EP0699755A3 (de) Verfahren zur Herstellung modifizierter Immunoglobulinen mit reduzierter Immunogenität der variablen Domänen einer murinen Antikörpers, Zusammensetzungen die diese enthalten
DE69535243D1 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DE69429092D1 (de) Verfahren zur kontrolle von b-zellenpopulation
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
PT100195A (pt) Anticorpos monoclonais quimericos e humanos que se ligam a epitopos de receptores de factor de crescimento da epiderme, seus vectores de expressao, processo de preparacao e composicoes farmaceuticas que os contem
DE68925226D1 (de) Monoklonale Antikörper
NO913428L (no) Humant intra-acrosomalt sperma-antigen for anvendelse i en befruktningshindrende vaksine.
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
EP0493446A4 (en) Treatment of autoimmune disease
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
AU626684B2 (en) Mouse monoglonal antibodies for post-exposure treatment of rabies
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
NO933394L (no) Omformede monoklonale antistoffer mot en immunoglobulin isotype
McNAMARA et al. Regulatory idiotopes. Induction of idiotype-recognizing helper T cells by free light and heavy chains.
BR9305557A (pt) Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
ES2119785T3 (es) Anticuerpos monoclonales contra la toxina tetanica y composiciones farmaceuticas que los contienen.
ATE143377T1 (de) Schimäre immunoglobuline für cd4-rezeptoren
Wilkinson et al. Tolerogenic polyethylene glycol derivatives of xenogeneic monoclonal immunoglobulins
Cerny et al. Properties of anti-idiotypic T cell lines propagated with syngeneic B lymphocytes. I. T cells bind intact idiotypes and discriminate between the somatic idiotypic variants in a manner similar to the anti-idiotopic antibodies.
KR960040375A (ko) 표피성장인자 수용체에 대한 면역반응을 유도하는 항-이디오타입 항체

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1059088

Country of ref document: EP